The participant has received radionuclide treatment within 6 weeks of the first dose of study treatment
Radionuclide treatment within 6 weeks of the first dose of study drug in this study
mCRPC EXPANSION COHORT: The patient has received radionuclide treatment within 6 weeks prior to the first dose of the study treatment
Received radionuclide treatment (i.e. iodine [I]-131 meta-iodo-benzyl guanidine) within 6 months of the first dose of study treatment
The subject has received radionuclide treatment within 6 weeks of the first dose of study treatment
The subject has received radionuclide treatment within 6 weeks of the first dose of study treatment
The subject has received radionuclide treatment within 6 weeks of the first dose of study treatment
No prior radionuclide treatment within 6 weeks of the first dose of study treatment
Radionuclide treatment, including yttrium-90 treatment, within 6 weeks of the first dose of study treatment
The subject has received radionuclide treatment within 6 weeks before the first dose of study treatment
Systemic therapeutic radionuclide delivery within 30 days prior to treatment
The subject has received radionuclide treatment within 6 weeks prior to the first dose of the study treatment
Biological agents (antibodies, immune modulators, cytokines, or vaccines) or radionuclide treatment within 6 weeks of the first dose of study treatment
The participant has received radionuclide treatment within 6 weeks of the first dose of study treatment
Cannot have received radionuclide treatment within 6 weeks of first dose of study treatment
The subject has received radionuclide treatment within 6 weeks of the first dose of study treatment
The subject has received radionuclide treatment within 6 weeks of the first dose of study treatment
The subject has received radionuclide treatment within 6 weeks of the first dose of study treatment
The subject has received radionuclide treatment within 6 weeks of the first dose of study treatment
Major surgery or other loco regional treatment within 4 weeks before the first dose of study drug or radionuclide treatment within 8 weeks
